When cancer progresses on endocrine therapy, the next step is likely either a biopsy to gather tissue for testing or a liquid ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

The U.S. Food and Drug Administration (FDA) has approved its Guardant360® CDx as a companion diagnostic to identify patients ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results. Among ...

Cancer treatment is so much more exciting now than it was even 5 or 10 years ago, because not only are treatments so much better, but they're so much easier to take. The stage of cancer is one of the ...

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy. The Food and Drug Administration (FDA) has approved Datroway ® (datopotamab ...

Triple-negative breast cancer does not respond to targeted breast cancer treatments, which limits treatment to primarily ...

Tislelizumab-jsgr approved with chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma, showing significant survival benefits. RATIONALE-305 study demonstrated a 20% ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...